Premature Coronary Artery Disease and Plasma Levels of Interleukins; a Systematic Scoping Review and Meta-Analysis
Archives of Academic Emergency Medicine,
Vol. 10 No. 1 (2022),
1 January 2022
,
Page e51
https://doi.org/10.22037/aaem.v10i1.1605
Abstract
Introduction: Interleukins (ILs) can act as a predictive indicator of Premature Coronary Artery Disease (pCAD) and may be useful in screening of high-risk patients. However, there is no consensus on the relationship of serum levels of ILs and pCAD, yet. As a result, this study has been conducted in order to review the literature on the relationship between serum levels of different ILs and pCAD.
Methods: Medline, Scopus, Embase, and Web of Science databases were searched until December 7th 2020. Two reviewers independently screened and summarized eligible articles. A meta-analysis was performed to assess the relationship of ILs and pCAD.
Results: 12 case-control articles were included. IL-6 plasma changes do happen in pCAD patients with a standardized mean difference (SMD) of 0.51 (95% CI: 0.12-0.90; p=0.010) compared with the control group. This difference was also observed when evaluating the plasma levels of IL-1 and IL-17, with an SMD of 1.42 (95% CI: 1.11-1.73; p<0.001) and 0.59 (95% CI: 0.14-1.04; p=0.011), respectively. Meanwhile, no significant difference existed in plasma levels of IL-10 (SMD=0.26; 95% CI: -0.17-0.70; p=0.236), and IL-18 (SMD=1.44; 95% CI: -0.19-3.07; p=0.083) between pCAD patients and those in the control group.
Conclusion: Low level of evidence showed that there may be a significant relationship between increased plasma levels of ILs and the occurrence of pCAD. As a result, prospective cohort studies with serial assessments of serum ILs during follow up period, focusing on controlling classical risk factors of pCAD and increase in level of ILs, should be conducted.
- Coronary artery disease
- cardiovascular disease
- interleukins
- Prognosis
- Biomarkers
How to Cite
References
Anthony D, George P, Eaton CB. Cardiac risk factors: environmental, sociodemographic, and behavioral cardiovascular risk factors. FP Essent. 2014;421:16-20.
Williams RA. Cardiovascular disease in African American women: a health care disparities issue. J Natl Med Assoc. 2009;101(6):536-40.
Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020:E139-E596.
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44-e164.
Mates J, Mademont-Soler I, Fernandez-Falgueras A, Sarquella-Brugada G, Cesar S, Arbelo E, et al. Sudden Cardiac Death and Copy Number Variants: What Do We Know after 10 Years of Genetic Analysis? Forensic Sci Int Genet. 2020;47:102281.
Angelantonio ED, Butterworth AS. Clinical Utility of Genetic Variants for Cardiovascular Risk Prediction. Circ Cardiovasc Genet. 2012;5(4):387-90.
Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Postgrad Med J. 2008;84(993):368-71.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207.
Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108(24):2957-63.
Bacchiega BC, Bacchiega AB, Usnayo MJG, Bedirian R, Singh G, Pinheiro GdRC. Interleukin 6 inhibition and coronary artery disease in a high‐risk population: a prospective community‐based clinical study. J Am Heart Assoc. 2017;6(3):e005038.
Szekely Y, Arbel Y. A review of Interleukin-1 in heart disease: where do we stand today? Cardiol Ther. 2018;7(1):25-44.
Wainstein MV, Mossmann M, Araujo GN, Gonçalves SC, Gravina GL, Sangalli M, et al. Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography. Diabetol Metab Syndr. 2017;9(1):1-7.
Health NIo. Study Quality Assessment Tools| National Heart, Lung, and Blood Institute (NHLBI) United States: National Institutes of Health; 2014 [Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.
Ansari WM, Humphries SE, Naveed AK, Khan OJ, Khan DA, Khattak EH. Effect of Coronary Artery Disease risk SNPs on serum cytokine levels and cytokine imbalance in Premature Coronary Artery Disease. Cytokine. 2019;122:154060.
Antoniades C, Tousoulis D, Vasiliadou C, Pitsavos C, Chrysochoou C, Panagiotakos D, et al. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. J Am Coll Cardiol. 2005;46(6):1101-9.
Ghatge M, Sharma A, Vangala RK. Association of γ-glutamyl transferase with premature coronary artery disease. Biomed Rep. 2016;4(3):307-12.
Cho S, Hak Lee S, Park S, Ha Jee S, Ki Hong M, Chung N, et al. The additive value of multiple biomarkers in prediction of premature coronary artery disease. Acta Cardiol. 2015;70(2):205-10.
Demir B, Ünğan İ, Oflar E, Khankishiyev V, Pirhan O, Demir E, et al. Elevated Serum Interleukin 17A Level in Patients with Premature Acute Coronary Syndrome. Turkiye Klinikleri Cardiovasc Sci. 2015;27(2):53-60.
Khan DA, Ansari WM, Khan FA. Pro/anti-inflammatory cytokines in the pathogenesis of premature coronary artery disease. J Interferon Cytokine Res. 2011;31(7):561-7.
Lundman P, Boquist S, Samnegård A, Bennermo M, Held C, Ericsson C-G, et al. A high-fat meal is accompanied by increased plasma interleukin-6 concentrations. Nutr Metab Cardiovasc Dis. 2007;17(3):195-202.
Phulukdaree A, Khan S, Ramkaran P, Govender R, Moodley D, Chuturgoon AA. The Interleukin-6− 147 G/C Polymorphism Is Associated with Increased Risk of Coronary Artery Disease in Young South African Indian Men. Metab Syndr Relat Disord. 2013;11(3):205-9.
Posadas-Sánchez R, Angeles-Martínez J, Pérez-Hernández N, Rodríguez-Pérez JM, López-Bautista F, Flores-Dominguez C, et al. The IL-10-1082 (rs1800896) G allele is associated with a decreased risk of developing premature coronary artery disease and some IL-10 polymorphisms were associated with clinical and metabolic parameters. The GEA study. Cytokine. 2018;106:12-8.
Thompson SR, McCaskie PA, Beilby JP, Hung J, Jennens M, Chapman C, et al. IL18 haplotypes are associated with serum IL-18 concentrations in a population-based study and a cohort of individuals with premature coronary heart disease. Clin Chem. 2007;53(12):2078-85.
Pauli N, Puchałowicz K, Kuligowska A, Krzystolik A, Dziedziejko V, Safranow K, et al. Associations between IL-6 and echo-parameters in patients with early onset coronary artery disease. Diagnostics. 2019;9(4):189.
Wang Y, Yu X, Wang P, Bao Z. Interleukin 10 gene-627 polymorphisms in Chinese patients with early-onset coronary heart disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005;22(6):679-81.
Satti HS, Hussain S, Javed Q. Association of interleukin-6 gene promoter polymorphism with coronary artery disease in Pakistani families. ScientificWorldJournal. 2013;2013:538365.
Ghazouani L, Abboud N, Khalifa SBH, Added F, Khalfallah AB, Nsiri B, et al. -174G> C interleukin-6 gene polymorphism in Tunisian patients with coronary artery disease. Ann Saudi Med. 2011;31(1):40-4.
- Abstract Viewed: 1220 times
- pdf Downloaded: 562 times
Download Statastics
Make a Submission
SJR
COPE
